JP2022500493A - 血管疾患の治療におけるカゼインキナーゼ1阻害剤の使用 - Google Patents
血管疾患の治療におけるカゼインキナーゼ1阻害剤の使用 Download PDFInfo
- Publication number
- JP2022500493A JP2022500493A JP2021537501A JP2021537501A JP2022500493A JP 2022500493 A JP2022500493 A JP 2022500493A JP 2021537501 A JP2021537501 A JP 2021537501A JP 2021537501 A JP2021537501 A JP 2021537501A JP 2022500493 A JP2022500493 A JP 2022500493A
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- disease
- heart
- myogenic
- vascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019553 vascular disease Diseases 0.000 title claims abstract description 18
- 229940076606 Casein kinase 1 inhibitor Drugs 0.000 title claims description 48
- 238000011282 treatment Methods 0.000 title claims description 16
- 102000008122 Casein Kinase I Human genes 0.000 claims abstract description 75
- 108010049812 Casein Kinase I Proteins 0.000 claims abstract description 75
- 239000003112 inhibitor Substances 0.000 claims abstract description 30
- 206010019280 Heart failures Diseases 0.000 claims description 49
- 206010020772 Hypertension Diseases 0.000 claims description 30
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 27
- 230000002792 vascular Effects 0.000 claims description 19
- 208000029078 coronary artery disease Diseases 0.000 claims description 18
- 208000032843 Hemorrhage Diseases 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 230000016507 interphase Effects 0.000 claims description 13
- 208000006011 Stroke Diseases 0.000 claims description 11
- 208000002330 Congenital Heart Defects Diseases 0.000 claims description 9
- 208000005189 Embolism Diseases 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 9
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 9
- 208000001435 Thromboembolism Diseases 0.000 claims description 9
- 206010047249 Venous thrombosis Diseases 0.000 claims description 9
- 208000007474 aortic aneurysm Diseases 0.000 claims description 9
- 208000028831 congenital heart disease Diseases 0.000 claims description 9
- 208000018578 heart valve disease Diseases 0.000 claims description 9
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 210000004165 myocardium Anatomy 0.000 claims description 9
- 208000004124 rheumatic heart disease Diseases 0.000 claims description 9
- 230000000144 pharmacologic effect Effects 0.000 claims description 7
- 101150047910 CSNK1D gene Proteins 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000003797 telogen phase Effects 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 238000010586 diagram Methods 0.000 abstract 1
- 230000001114 myogenic effect Effects 0.000 description 102
- 230000004044 response Effects 0.000 description 78
- 210000001367 artery Anatomy 0.000 description 39
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 26
- 102000003390 tumor necrosis factor Human genes 0.000 description 26
- 206010047139 Vasoconstriction Diseases 0.000 description 22
- 230000025033 vasoconstriction Effects 0.000 description 22
- 230000002441 reversible effect Effects 0.000 description 21
- 230000011664 signaling Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 208000010125 myocardial infarction Diseases 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 17
- 210000002027 skeletal muscle Anatomy 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 230000001404 mediated effect Effects 0.000 description 15
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 14
- 229960001802 phenylephrine Drugs 0.000 description 14
- 230000026731 phosphorylation Effects 0.000 description 14
- 238000006366 phosphorylation reaction Methods 0.000 description 14
- 210000003205 muscle Anatomy 0.000 description 13
- 230000004217 heart function Effects 0.000 description 12
- OGKYMFFYOWUTKV-UHFFFAOYSA-N N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide Chemical compound C1=NC=C2C(S(=O)(=O)NCCN)=CC=C(Cl)C2=C1 OGKYMFFYOWUTKV-UHFFFAOYSA-N 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 230000010060 microvascular dysfunction Effects 0.000 description 11
- 102100037402 Casein kinase I isoform delta Human genes 0.000 description 10
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 10
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 108010047048 Casein Kinase Idelta Proteins 0.000 description 9
- 230000002060 circadian Effects 0.000 description 9
- 230000036581 peripheral resistance Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 230000009885 systemic effect Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 208000034158 bleeding Diseases 0.000 description 8
- 230000000740 bleeding effect Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000001543 one-way ANOVA Methods 0.000 description 8
- 230000010355 oscillation Effects 0.000 description 8
- 206010002383 Angina Pectoris Diseases 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000000284 resting effect Effects 0.000 description 6
- 238000012762 unpaired Student’s t-test Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 210000002460 smooth muscle Anatomy 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000000004 hemodynamic effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000005166 vasculature Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000002565 arteriole Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 108010008165 Etanercept Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 102000018594 Tumour necrosis factor Human genes 0.000 description 2
- 108050007852 Tumour necrosis factor Proteins 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000010455 autoregulation Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000007248 cellular mechanism Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 230000006438 vascular health Effects 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101150059573 AGTR1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101001026336 Homo sapiens Casein kinase I isoform delta Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 208000035967 Long Term Adverse Effects Diseases 0.000 description 1
- 101150018665 MAPK3 gene Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 1
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 1
- 102000011131 Myosin-Light-Chain Phosphatase Human genes 0.000 description 1
- 108010037801 Myosin-Light-Chain Phosphatase Proteins 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000231739 Rutilus rutilus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100039024 Sphingosine kinase 1 Human genes 0.000 description 1
- 101150033527 TNF gene Proteins 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000024321 chromosome segregation Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- -1 ester salts Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003975 mesenteric artery Anatomy 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000036584 pressor response Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011867 re-evaluation Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 235000021023 sodium intake Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 108010035597 sphingosine kinase Proteins 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
1. Bayliss. On the local reactions of the arterial wall to changes of internal pressure. J Physiol. 1902;28:220-231.
2. Hill et al. Invited review: arteriolar smooth muscle mechanotransduction: Ca(2+) signaling pathways underlying myogenic reactivity. J Appl Physiol (1985). 2001;91:973-983.
3. Schubert et al. The emerging role of Ca2+ sensitivity regulation in promoting myogenic vasoconstriction. Cardiovasc Res. 2008;77:8-18.
4. Cole et al. Role of myosin light chain kinase and myosin light chain phosphatase in the resistance arterial myogenic response to intravascular pressure. Arch Biochem Biophys. 2011;510:160-173.
5. Lidington et al. Capitalizing on diversity: an integrative approach towards the multiplicity of cellular mechanisms underlying myogenic responsiveness. Cardiovasc Res. 2013;97:404-412.
6. Kuo et al. Coronary arteriolar myogenic response is independent of endothelium. Circ Res. 1990;66:860-866.
7. Falcone et al. Endothelial independence of myogenic response in isolated skeletal muscle arterioles. Am J Physiol. 1991;260:H130-H135.
8. Meininger et al. Cellular mechanisms involved in the vascular myogenic response. Am J Physiol. 1992;263:H647-H659.
9. Metting et al. Systemic vascular autoregulation amplifies pressor responses to vasoconstrictor agents. Am J Physiol. 1989;256:R98-105.
10. Metting et al. Quantitative contribution of systemic vascular autoregulation in acute hypertension in conscious dogs. J Clin Invest. 1989;84:1900-1905.
11. Petersen et al. Coronary artery myogenic response in a genetic model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2002;283:H2244-H2249.
12. Hoefer et al. Sphingosine-1-phosphate-dependent activation of p38 MAPK maintains elevated peripheral resistance in heart failure through increased myogenic vasoconstriction. Circ Res. 2010;107:923-933.
13. Gschwend et al. Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT1 receptor blockade. Br J Pharmacol. 2003;139:1317.
14. Sauve et al. Tumor Necrosis Factor/Sphingosine-1-Phosphate Signaling Augments Resistance Artery Myogenic Tone in Diabetes. Diabetes. 2016;65:1916-1928.
15. Ungvari et al. Increased myogenic tone in skeletal muscle arterioles of diabetic rats. Possible role of increased activity of smooth muscle Ca2+ channels and protein kinase C. Cardiovasc Res. 1999;43:1018-1028.
16. Matrougui et al. High sodium intake decreases pressure-induced (myogenic) tone and flow-induced dilation in resistance arteries from hypertensive rats. Hypertension. 1998;32:176-179.
17. Rowell. Human cardiovascular adjustments to exercise and thermal stress. Physiol Rev. 1974;54:75-159.
18. Kroetsch et al. Constitutive smooth muscle tumour necrosis factor regulates microvascular myogenic responsiveness and systemic blood pressure. Nat Commun. 2017;8:14805.
19. Watts et al. A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in reverse signaling. EMBO J. 1999;18:2119-2126.
20. Venerando et al. Casein kinase: the triple meaning of a misnomer. Biochem J. 2014;460:141 156.
21. Gross et al. Casein kinase I: spatial organization and positioning of a multifunctional protein kinase family. Cell Signal. 1998;10:699-711.
22. Knippschild et al. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cell Signal. 2005;17:675-689.
23. Cheong et al. Casein kinase 1: Complexity in the family. Int J Biochem Cell Biol. 2011;43:465 469.
24. Pulgar et al. Optimal sequences for non-phosphate-directed phosphorylation by protein kinase CK1 (casein kinase-1)--a re-evaluation. Eur J Biochem. 1999;260:520-526.
25. Roach. Multisite and hierarchal protein phosphorylation. J Biol Chem. 1991;266:14139-14142.
Claims (22)
- 血管疾患および/または心血管疾患の予防および/または治療に使用するためのカゼインキナーゼ1(CK1)阻害剤。
- 前記血管疾患または前記心血管疾患が、冠動脈疾患(CAD)、脳卒中、心不全、高血圧性心疾患、リウマチ性心疾患、心筋症、心拍異常、先天性心疾患、心臓弁膜症、心臓炎、大動脈瘤、末梢動脈疾患、血栓塞栓症、静脈血栓症、くも膜下出血および高血圧症からなる群から選択される、請求項1に記載の使用のためのCK1阻害剤。
- 前記血管疾患または前記心血管疾患が、心不全、くも膜下出血および高血圧症からなる群から選択される、請求項2に記載の使用のためのCK1阻害剤。
- 前記CK1阻害剤がCK1δおよび/またはCK1εに対して選択的である、前記請求項のいずれか一項に記載の使用のためのCK1阻害剤。
- 前記CK1阻害剤が、PF−670462、PF−4800567およびそれらの混合物からなる群から選択される、請求項3に記載の使用のためのCK1阻害剤。
- 前記CK1阻害剤がPF−670462である、請求項4に記載の使用のためのCK1阻害剤。
- 前記CK1阻害剤がPF−4800567である、請求項4に記載の使用のためのCK1阻害剤。
- 前記CK1阻害剤が1日1回、2回または3回患者に投与される、前記請求項のいずれか一項に記載の使用のためのCK1阻害剤。
- 前記CK1阻害剤が、対象の休息段階に少なくとも1つのCK1の最大の薬理学的効果を提供する投与計画に従って対象に投与される、請求項7に記載の使用のためのCK1阻害剤。
- 前記CK1阻害剤が、休息段階または休息段階の−2時間から+2時間、好ましくは休息段階の−1時間から+1時間において、少なくとも1つのCK1の最大の薬理学的効果を提供する投与計画に従って対象に投与される、請求項8に記載の使用のためのCK1阻害剤。
- 有効量の少なくとも1つのCK1阻害剤を、それを必要とする患者に投与するステップを含んで行うことによる、血管疾患および/または心血管疾患の予防および/または治療のための方法。
- 前記血管疾患または前記心血管疾患が、冠動脈疾患(CAD)、脳卒中、心不全、高血圧性心疾患、リウマチ性心疾患、心筋症、心拍異常、先天性心疾患、心臓弁膜症、心臓炎、大動脈瘤、末梢動脈疾患、血栓塞栓症、静脈血栓症、くも膜下出血および高血圧症からなる群から選択される、請求項10に記載の方法。
- 前記血管疾患または前記心血管疾患が、心不全、くも膜下出血および高血圧症からなる群から選択される、請求項11に記載の方法。
- 前記CK1阻害剤がCK1δおよび/またはCK1εに対して選択的である、請求項10から12のいずれか一項に記載の方法。
- 前記CK1阻害剤が、PF−670462、PF−4800567およびそれらの混合物からなる群から選択される、請求項13に記載の方法。
- 前記CK1阻害剤がPF−670462である、請求項14に記載の方法。
- 前記CK1阻害剤がPF−4800567である、請求項14に記載の方法。
- 前記CK1阻害剤が1日1回、2回または3回前記患者に投与される、請求項10から16のいずれか一項に記載の方法。
- 前記CK1阻害剤が、前記患者の休息段階に少なくとも1つのCK1の最大の薬理学的効果を提供する投与計画に従って対象に投与される、請求項17に記載の方法。
- 前記CK1阻害剤が、休息段階または休息段階の−2時間から約+2時間において、少なくとも1つのCK1の最大の薬理学的効果を提供する投与計画に従って前記患者に投与される、請求項18に記載の方法。
- 前記CK1阻害剤が、休息段階の約−1時間から約+1時間において、少なくとも1つのCK1の最大の薬理学的効果を提供する投与計画に従って前記患者に投与される、請求項18に記載の方法。
- 前記患者が哺乳動物、好ましくはヒトである、前記請求項のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18193320 | 2018-09-09 | ||
EP18193320.1 | 2018-09-09 | ||
PCT/EP2019/074012 WO2020049190A1 (en) | 2018-09-09 | 2019-09-09 | Use of casein kinase 1 inhibitors for treating vascular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022500493A true JP2022500493A (ja) | 2022-01-04 |
Family
ID=63556151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021537501A Pending JP2022500493A (ja) | 2018-09-09 | 2019-09-09 | 血管疾患の治療におけるカゼインキナーゼ1阻害剤の使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220047598A1 (ja) |
EP (1) | EP3846818A1 (ja) |
JP (1) | JP2022500493A (ja) |
KR (1) | KR20210072768A (ja) |
CN (1) | CN113301900A (ja) |
AU (1) | AU2019336540A1 (ja) |
CA (1) | CA3111848A1 (ja) |
CL (1) | CL2021000580A1 (ja) |
MX (1) | MX2021002652A (ja) |
WO (1) | WO2020049190A1 (ja) |
ZA (1) | ZA202102274B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3273955A4 (en) | 2015-03-23 | 2019-05-01 | The University of Melbourne | TREATMENT OF RESPIRATORY DISEASES |
US11752151B2 (en) * | 2021-07-12 | 2023-09-12 | Buddhist Tzu Chi Medical Foundation | Method for enhancing hair growth |
WO2023129377A1 (en) * | 2022-01-03 | 2023-07-06 | The Johns Hopkins University | Methods and materials for treating heart attack |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014023271A1 (en) * | 2012-08-08 | 2014-02-13 | Masarykova Univerzita | Casein kinase 1 inhibitors for the treatment of b-cell chronic lymphocytic|leukemia |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004035076A1 (en) * | 2002-10-15 | 2004-04-29 | Chiron Corporation | Treatment of tnf-alpha-mediated disorders with casein kinase i epsilon inhibitors |
PL2493876T3 (pl) * | 2009-10-28 | 2014-06-30 | Pfizer | Pochodne imidazolu jako inhibitory kinazy kazeinowej |
AU2011290238B8 (en) * | 2010-08-09 | 2015-09-03 | Nb Health Laboratory Co. Ltd. | Inhibitor of casein kinase 1delta and casein kinase 1E |
WO2013074587A1 (en) * | 2011-11-16 | 2013-05-23 | Duke University | Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction |
-
2019
- 2019-09-09 EP EP19762832.4A patent/EP3846818A1/en active Pending
- 2019-09-09 CN CN201980068381.8A patent/CN113301900A/zh active Pending
- 2019-09-09 KR KR1020217010068A patent/KR20210072768A/ko unknown
- 2019-09-09 CA CA3111848A patent/CA3111848A1/en active Pending
- 2019-09-09 AU AU2019336540A patent/AU2019336540A1/en active Pending
- 2019-09-09 WO PCT/EP2019/074012 patent/WO2020049190A1/en unknown
- 2019-09-09 JP JP2021537501A patent/JP2022500493A/ja active Pending
- 2019-09-09 MX MX2021002652A patent/MX2021002652A/es unknown
- 2019-09-19 US US17/274,773 patent/US20220047598A1/en active Pending
-
2021
- 2021-03-09 CL CL2021000580A patent/CL2021000580A1/es unknown
- 2021-04-06 ZA ZA2021/02274A patent/ZA202102274B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014023271A1 (en) * | 2012-08-08 | 2014-02-13 | Masarykova Univerzita | Casein kinase 1 inhibitors for the treatment of b-cell chronic lymphocytic|leukemia |
Non-Patent Citations (3)
Title |
---|
LACO, F. ET AL., J MOL CELL CARDIOL, vol. 80, JPN6023029817, 2015, pages 56 - 70, ISSN: 0005114131 * |
OBAL, D. ET AL., CIRCULATION, vol. Vol. 134, Suppl. 1, Abstract No. 18896, JPN6023029815, 2016, ISSN: 0005114132 * |
SLAVI, N. ET AL., PROC NATL ACAD SCI U S A, vol. 115, no. 26, JPN6023029816, June 2018 (2018-06-01), pages 5934 - 5943, ISSN: 0005114130 * |
Also Published As
Publication number | Publication date |
---|---|
AU2019336540A1 (en) | 2021-05-13 |
CN113301900A (zh) | 2021-08-24 |
KR20210072768A (ko) | 2021-06-17 |
US20220047598A1 (en) | 2022-02-17 |
WO2020049190A1 (en) | 2020-03-12 |
CL2021000580A1 (es) | 2022-04-18 |
ZA202102274B (en) | 2022-07-27 |
CA3111848A1 (en) | 2020-03-12 |
EP3846818A1 (en) | 2021-07-14 |
MX2021002652A (es) | 2021-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tran et al. | Endothelial nitric oxide synthase (eNOS) and the cardiovascular system: in physiology and in disease states | |
Kanda et al. | Rho‐kinase as a molecular target for insulin resistance and hypertension | |
Vincent et al. | Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium | |
Ortiz et al. | Cardiovascular and renal control in NOS-deficient mouse models | |
Earley et al. | Transient receptor potential channels in the vasculature | |
Boo et al. | Shear stress stimulates phosphorylation of eNOS at Ser635 by a protein kinase A-dependent mechanism | |
JP2022500493A (ja) | 血管疾患の治療におけるカゼインキナーゼ1阻害剤の使用 | |
Kim et al. | Hemodynamic alterations in cirrhosis and portal hypertension | |
Castillero et al. | Activin type II receptor ligand signaling inhibition after experimental ischemic heart failure attenuates cardiac remodeling and prevents fibrosis | |
Firth et al. | Animal models of pulmonary hypertension: Rho kinase inhibition | |
Grossini et al. | Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig | |
Wang et al. | NO-induced vasodilation correlates directly with BP in smooth muscle-Na/Ca exchanger-1-engineered mice: elevated BP does not attenuate endothelial function | |
Kang et al. | Effect of ATP-sensitive potassium channel agonists on sympathetic hyperinnervation in postinfarcted rat hearts | |
Huang et al. | The Janus-faced role of Piezo1 in cardiovascular health under mechanical stimulation | |
Cammalleri et al. | The β3 adrenoceptor in proliferative retinopathies:“Cinderella” steps out of its family shadow | |
Yuan et al. | CCR7/p-ERK1/2/VEGF signaling promotes retinal neovascularization in a mouse model of oxygen-induced retinopathy | |
US20080206219A1 (en) | Novel Indications for Transforming Growth Factor-Beta Regulators | |
Cheng et al. | Role of RACK1 in the differential proliferative effects of neuropeptide Y1–36 and peptide YY1–36 in SHR vs. WKY preglomerular vascular smooth muscle cells | |
Wang et al. | c‐Jun N‐terminal Kinase mediates prostaglandin‐induced sympathoexcitation in rats with chronic heart failure by reducing GAD 1 and GABRA 1 expression | |
Ai et al. | Current status of drugs targeting PDGF/PDGFR | |
Chan et al. | Pulmonary vascular disease related to hemodynamic stress in the pulmonary circulation | |
Castillero et al. | Translational Physiology: Activin type II receptor ligand signaling inhibition after experimental ischemic heart failure attenuates cardiac remodeling and prevents fibrosis | |
Kamynina | Furthering the understanding of the redox control of soluble Epoxide Hydrolase and Protein Kinase G in the cardiovascular system | |
Tappia et al. | Regulation of phospholipase C in cardiac hypertrophy | |
Langer et al. | AMPK as a mediator of tissue preservation: time for a shift in dogma? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220909 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220915 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230725 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231020 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240124 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240416 |